Final Progression-Free Survival Analyses for Lanreotide Autogel/Depot 120 mg in Metastatic Enteropancreatic Neuroendocrine Tumors: The CLARINET Extension Study

被引：0

作者：

Wolin, Edward M. ^{[1
]}

Pavel, Marianne E. ^{[2
]}

Cwikla, Jaroslaw B. ^{[3
]}

Phan, Alexandria T. ^{[4
]}

Raderer, Markus ^{[5
]}

Sedlackova, Eva ^{[6
,7
]}

Cadiot, Guillaume ^{[8
]}

Capdevila, Jaume ^{[9
]}

Wall, Lucy ^{[10
]}

Rindi, Guido ^{[11
]}

Lombard-Bohas, Catherine ^{[12
]}

Liyanage, Nilani ^{[13
]}

Thanh, Xuan-Mai Truong ^{[14
]}

Ruszniewski, Philippe B. ^{[15
]}

Caplin, Martyn E. ^{[16
]}

Investigators, Clarinet ^{[17
]}

机构：

[1] Montefiore Einstein Ctr Canc Care, New York, NY USA

[2] Univ Klinikum Erlangen, Erlangen, Germany

[3] Univ Warmia & Mazury, Olsztyn, Poland

[4] Canc Treatment Ctr Amer, Atlanta, GA USA

[5] Univ Hosp, Vienna, Austria

[6] First Fac Med, Prague, Czech Republic

[7] Gen Teaching Hosp, Prague, Czech Republic

[8] Robert Debre Hosp, Reims, France

[9] Vall dHebron Univ Hosp, Barcelona, Spain

[10] Western Gen Hosp, Edinburgh, Midlothian, Scotland

[11] Univ Cattolica Sacro Cuore, Rome, Italy

[12] Hosp Civils Lyon, Edouard Herriot Hosp, Lyon, France

[13] Ipsen, Les Ulis, France

[14] Ipsen, Boulogne, France

[15] Beaujon Hosp, Clichy, France

[16] Royal Free Hosp, London, England

[17] CLARINET Study Investigators, London, England

来源：

PANCREAS | 2018年 / 47卷 / 03期

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

页码：358 / 359

页数：2

共 50 条

[41] Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study
Faivre, S.
Niccoli, P.
Castellano, D.
Valle, J. W.
Hammel, P.
Raoul, J. -L.
Vinik, A.
Van Cutsem, E.
Bang, Y. -J.
Lee, S. -H.
Borbath, I.
Lombard-Bohas, C.
Metrakos, P.
Smith, D.
Chen, J. -S.
Ruszniewski, P.
Seitz, J. -F.
Patyna, S.
Lu, D. R.
Ishak, K. J.
Raymond, E.
ANNALS OF ONCOLOGY, 2017, 28 (02) : 339 - 343
[42] Efficacy and safety of lanreotide autogel (LAN) 120 mg every 14 days in progressive pancreatic or midgut neuroendocrine tumours (NETs): CLARINET FORTE study results
Pavel, M.
Cwikla, J. B.
Lombard-Bohas, C.
Borbath, I.
Shah, T.
Pape, U-F.
Thanh, X-M. Truong
Houchard, A.
Ruszniewski, P.
ANNALS OF ONCOLOGY, 2020, 31 : S773 - S773
[43] Establishing the Quantitative Relationship Between Lanreotide AutogelA®, Chromogranin A, and Progression-Free Survival in Patients with Nonfunctioning Gastroenteropancreatic Neuroendocrine Tumors
Buil-Bruna, Nuria
Dehez, Marion
Manon, Amandine
Thi Xuan Quyen Nguyen
Troconiz, Inaki F.
AAPS JOURNAL, 2016, 18 (03): : 703 - 712
[44] DOSE EXTENSION AND COSTS OF LANREOTIDE AUTOGEL 120 MG USED IN ROUTINE NEUROENDOCRINE TUMORS CARE IN POLAND-2-YEARS DATA FROM LANRO-NET STUDY
Orlewska, E.
Bednarczuk, T.
Kaminski, G.
Budlewski, T.
Kos-Kudla, B.
VALUE IN HEALTH, 2016, 19 (07) : A728 - A728
[45] u Effect of lanreotide depot (LAN) on 5-hydroxyindoleacetic acid (5HIAA) and chromogranin A (CgA) in gastroenteropa ncreatic neuroendocrine (GEP NET) tumors: Correlation with tumor response and progression-free survival (PFS) from the phase III CLARINET study.
Phan, Alexandria T.
Wolin, Edward M.
Liyanage, Nilani
Mirakhur, Beloo
Pitman, Susan W.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[46] Long-term safety and efficacy of lanreotide autogel in Japanese patients with neuroendocrine tumors: Final results of a phase II open-label extension study
Ito, Tetsuhide
Fujimori, Nao
Honma, Yoshitaka
Kudo, Atsushi
Hijioka, Susumu
Katsushima, Shinji
Kimura, Yasutoshi
Fukutomi, Akira
Hisamatsu, Seiichi
Nakajima, Akihiro
Shimatsu, Akira
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 (05) : E153 - E161
[47] CLARINET FORTE Baseline Characteristics: Lanreotide Autogel 120 mg (LAN) Every 14 Days in Patients With Progressive Pancreatic or Midgut Neuroendocrine Tumors During a Standard First-Line LAN Regimen
Ruszniewski, Philippe
Cwikla, Jaroslaw
Lombard-Bohas, Catherine
Borbath, Ivan
Shah, Tahir
Pape, Ulrich -Frank
Xuan-Mai Truong Thanh
Houchard, Aude
Pavel, Marianne
PANCREAS, 2020, 49 (03) : 484 - 485
[48] CLARINET FORTE: Characterization of Pharmacokinetics (PK), efficacy and safety in patients with progressive neuroendocrine tumors (NETs) treated with Lanreotide Autogel (LAN) 120 mg every 14 days (q14d)
Dehez, M.
Brendel, K.
Sarr, C.
Bjornsson, M.
Thanh, Truong X. M.
Pavel, M.
JOURNAL OF NEUROENDOCRINOLOGY, 2021, 33 : 133 - 133
[49] LanroNET, a non-interventional, prospective study to assess the resource utilization and cost of lanreotide autogel 120 mg in Polish patients with neuroendocrine tumors - results of interim analysis
Orlewska, Ewa
Bednarczuk, Tomasz
Kaminski, Grzegorz
Kos-Kudla, Beata
WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2014, 18 (06): : 442 - 447
[50] Association of upfront peptide receptor radionuclide therapy with progression-free survival among patients with enteropancreatic neuroendocrine tumors (vol 5, e220290, 2022)
Pusceddu, S.
Prinzi, N.
Tafuto, S.
JAMA NETWORK OPEN, 2022, 5 (03)

← 1 2 3 4 5 →